Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News May 17 2021 | Heart Failure Awareness 365: Minimizing the Financial Burden of Heart Failure Care Patient News Heart Failure Awareness 365 Patient Resource Read More May 14 2021 | Current Offerings in the HFSA Learning Center HFSA News HFSA Learning Center Professional Development Provider Education Read More May 12 2021 | Bayer’s Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Industry News Industry Read More May 6 2021 | FARXIGA approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type 2 diabetes Industry News Industry Read More Apr 27 2021 | Important Deadlines Approaching for HFSA Activities HFSA News Fellowship Annual Scientific Meeting HFSA Committees Read More Pagination First page « First Previous page ‹ Previous … Page 81 Page 82 Page 83 Page 84 Current page 85 Page 86 Page 87 Page 88 Page 89 … Next page Next › Last page Last »
May 17 2021 | Heart Failure Awareness 365: Minimizing the Financial Burden of Heart Failure Care Patient News Heart Failure Awareness 365 Patient Resource Read More
May 14 2021 | Current Offerings in the HFSA Learning Center HFSA News HFSA Learning Center Professional Development Provider Education Read More
May 12 2021 | Bayer’s Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes Industry News Industry Read More
May 6 2021 | FARXIGA approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type 2 diabetes Industry News Industry Read More
Apr 27 2021 | Important Deadlines Approaching for HFSA Activities HFSA News Fellowship Annual Scientific Meeting HFSA Committees Read More
